Compare ResMed Inc. (RMD) vs Sirius XM Holdings Inc (SIRI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ResMed Inc. vs Sirius XM Holdings Inc — how do they compare? ResMed Inc. trades at $197.45 (market cap $28.81B), while Sirius XM Holdings Inc trades at $30.24 (market cap $10.30B). The key difference: ResMed Inc. is far larger — about 2.8× Sirius XM Holdings Inc's market cap, and Sirius XM Holdings Inc pays the higher dividend (3.53%). Which is the better fit depends on your goals.
| RMD | SIRI | |
|---|---|---|
Market Cap | $28.81B | $10.30B |
Sector | Health | Media |
52-Week High | $293.73 | $31.22 |
52-Week Low | $182.82 | $19.92 |
Enterprise Value | $27.99B | $19.97B |
Dividend Yield | 1.21% | 3.53% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ResMed (RMD) trades at $195.8, down 1.6% on the day, with a bearish technical signal but strong fundamentals. Recent quarterly earnings have consistently beaten estimates, with Q1 2026 EPS of $2.86 exceeding the $2.80 forecast. The company sold its MatrixCare business for $490 million in July 2026 to sharpen focus on connected care, signaling strategic refinement. Revenue growth remains robust, climbing to $5.15 billion in 2025, with net income margins expanding to 27.44%.
The outlook is supported by solid earnings momentum and a consensus price target of $245.88, implying 25.6% upside. Risks include competitive pressures in medical equipment and reliance on sleep apnea market growth. Analyst sentiment is mixed with 40% buy ratings, but institutional selling by Baader Bank in Q1 2026 warrants monitoring.
Sirius XM (SIRI) trades at $30.29, down 0.98% on the day, with a bullish technical signal from moving averages and recent earnings beats. The stock shows solid fundamentals with a P/E of 12.97, net income margin of 9.86%, and a recent dividend payment. Revenue stabilized around $8.6B in 2025 after a dip in 2024, while debt-to-asset ratio improved to 35.63%.
Outlook is positive with analyst consensus at Buy (58% of ratings) and a $30.71 price target, though risks include competitive pressures and reliance on subscription growth. The YouTube ad partnership and inclusion in the S&P MidCap 400 provide catalysts, but investors should monitor Q2 2026 earnings due July 30 for confirmation of trends.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ResMed Inc.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →About Sirius XM Holdings Inc
SiriusXM Holdings is now composed of two businesses: SiriusXM and Pandora. SiriusXM transmits music, talk shows, sports, and news via its two satellite radio networks, primarily to consumers in vehicles who pay a subscription fee. The firm's radios come preinstalled on a wide range of light vehicles in the U.S. and Canada. The firm acquired Pandora Media in February 2019 via an all-stock transaction. Pandora is a streaming music platform that offers an ad-supported radio option and a paid on-demand service. Liberty Media owns 80% of SiriusXM, traded through its Liberty SiriusXM Group tracking stock.
Read more on SIRI →
